Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Hormonal immune-related side effects to immunotherapies
This study looked at the incidence, diagnosis and treatment of [...]
Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer
Further follow-up data from the phase 3 CLEAR study with [...]
Nivolumab plus cabozantinib for advanced non-clear cell kidney cancer
Updated results and further follow up from the CaboNivo study [...]
Promising new anti-cancer treatment for advanced kidney cancer
The results of a study with a new anti-cancer medication [...]
Atezolizumab plus cabozantinib for previously treated metastatic kidney cancer
The results of the CONTACT-03 study with atezolizumab plus cabozantinib [...]
Triple combination for previously untreated advanced non-clear cell kidney cancer
The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]
Cabozantinib plus atezolizumab in non-clear cell kidney cancer
The results from an extended follow-up of the phase 1b [...]
Triple combination improves survival in patients with advanced kidney cancer
Results from the phase 3 COSMIC-313 trial showed that adding [...]
Brain metastases from kidney cancer treated with first-line therapies
A recent study looked at the outcomes of patients with [...]
